Do activities of cytochrome P450 (CYP)3A, CYP2D6 and P-glycoprotein differ between healthy volunteers and HIV-infected patients?

Antivir Ther. 2010;15(7):975-83. doi: 10.3851/IMP1648.

Abstract

Background: In inflammation and infection, cytochrome P450 (CYP) enzyme activities are down-regulated. Information on possible discrepancies in activities of CYP enzymes and drug transporters between HIV-infected patients and healthy people is limited.

Methods: We used midazolam, dextromethorphan and digoxin as in vivo phenotyping probes for CYP3A (CYP3A4/5), CYP2D6 and P-glycoprotein activities, respectively, and compared these activities between 12 healthy Caucasian volunteers and 30 treatment-naive HIV-infected patients.

Results: Among the HIV-infected patients, the overall CYP3A activity (apparent oral midazolam clearance) was approximately 50% of the activity observed in healthy volunteers (point estimate 0.490, 90% confidence interval [CI] 0.377-0.638). The CYP2D6 activity (plasma ratio area under the curve [AUC]; AUC(dextromethorphan)/AUC(dextrorphan)) was essentially unchanged (point estimate 1.289, 90% CI 0.778-2.136). P-glycoprotein activity was slightly lower in patients (digoxin maximum concentration point estimate 1.304, 90% CI 1.034-1.644).

Conclusions: The overall CYP3A activity was approximately 50% lower in HIV-infected patients than in healthy volunteers. The CYP2D6 activity was highly variable, but, on average was not different between groups, whereas a marginally lower P-glycoprotein activity was observed in treatment-naive HIV-infected patients.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • ATP Binding Cassette Transporter, Subfamily B, Member 1 / genetics
  • ATP Binding Cassette Transporter, Subfamily B, Member 1 / metabolism*
  • Adolescent
  • Adult
  • Case-Control Studies
  • Cytochrome P-450 CYP2D6 / genetics
  • Cytochrome P-450 CYP2D6 / metabolism*
  • Cytochrome P-450 CYP3A / genetics
  • Cytochrome P-450 CYP3A / metabolism*
  • Dextromethorphan / pharmacokinetics
  • Digoxin / pharmacokinetics
  • Down-Regulation
  • HIV / drug effects
  • HIV Infections / drug therapy
  • HIV Infections / genetics*
  • HIV Protease Inhibitors / therapeutic use
  • Humans
  • Lopinavir
  • Male
  • Midazolam / pharmacokinetics
  • Middle Aged
  • Pyrimidinones / therapeutic use
  • Ritonavir / therapeutic use
  • Young Adult

Substances

  • ATP Binding Cassette Transporter, Subfamily B, Member 1
  • HIV Protease Inhibitors
  • Pyrimidinones
  • Lopinavir
  • Dextromethorphan
  • Digoxin
  • Cytochrome P-450 CYP2D6
  • Cytochrome P-450 CYP3A
  • CYP3A4 protein, human
  • Ritonavir
  • Midazolam